Mohamad Mohty - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Mohamad Mohty's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Mohamad Mohty
Verified
Associate Editor, Blood Cancer Journal
Beats
Politics the slippery paving stones of Europe life in France culture
gambling,firearms, smoking, vapes, politics
Content
Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT | Bone Marrow Transplanta
By Jaime Sanz, Myriam Labopin, Jurjen Versluis, Didier Blaise, Lorenzo Lazzari, Juan Montoro, Patrice Chevallier, Mi Ri Kwon, Jan Vydra, Eolia Brissot, Alexandros Spyridonidis, Simona Piemontese, Mohamad Mohty Verified| Nature Verified AbstractWe retrospectively analyzed the impact of conditioning intensity on transplant outcomes according to their cytogenetic/molecular risk in a cohort of 1823 patients with acute myeloid leukemia (AML) and intermediate- or adverse-risk cytogenetics in first complete remission (CR1). These patients received their first hematopoietic stem cell transplantation (HSCT) using post-transplant cyclophosphamide (PTCy).
By Mohamad Mohty Verified| OncoDaily@ Mohamad Mohty, Chairman of the IACH, shared his recent article on X:Just published in Clinical Hematology International, the official peer-reviewed open access academic journal of The International Academy for Clinical Hematology (IACH). The journal welcomes your contributions: no submission fees or other hidden charges for academic authors. How to perform a high-quality peer reviewAuthors:
Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT | Bone Marrow Transplanta
By Jaime Sanz, Myriam Labopin, Jurjen Versluis, Didier Blaise, Lorenzo Lazzari, Juan Montoro, Patrice Chevallier, Mi Ri Kwon, Jan Vydra, Eolia Brissot, Alexandros Spyridonidis, Simona Piemontese, Mohamad Mohty Verified| Nature Verified AbstractWe retrospectively analyzed the impact of conditioning intensity on transplant outcomes according to their cytogenetic/molecular risk in a cohort of 1823 patients with acute myeloid leukemia (AML) and intermediate- or adverse-risk cytogenetics in first complete remission (CR1). These patients received their first hematopoietic stem cell transplantation (HSCT) using post-transplant cyclophosphamide (PTCy).
Company Info
Blood Cancer Journal
Paris, Ile-de-France, France
+33 5 31 22 40 89